Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein disulfide isomerases (PDIs) are a family of enzymes primarily responsible for catalyzing the formation, breakage, and rearrangement (isomerization) of disulfide bonds in proteins. These processes are essential for proper protein folding and stability, particularly within the endoplasmic reticulum (ER) of eukaryotic cells. PDIs also possess chaperone activity, assisting in the correct folding or degradation of misfolded proteins. The human PDI gene family comprises 21 genes with diverse domain compositions and functions. Given their central role in proteostasis networks—especially UPR—PDIs have emerged as promising drug targets for conditions like cancer, neurodegeneration, diabetes, liver disease, and thrombosis.
Inhibition of disulfide bond formation/isomerization, disruption of protein folding and ER homeostasis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Disulfide Isomerase Family Proteins (PDI family).